George D. Demetri

Harvard University — United States

Medicine · Health Sciences

114h-index63.4kcitations637works17.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(271), Gastrointestinal Tumor Research and Treatment(231), Gastric Cancer Management and Outcomes(94), Lung Cancer Treatments and Mutations(77), Lymphoma Diagnosis and Treatment(57)

Publications637 total

Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
Scientific Reports·2025· 4 citedOpen Access
AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncology
2025Open Access
Abstract CT113: A first-in-human phase 1, multicenter, open-label study of M3554, a novel anti-GD2 antibody-drug conjugate (ADC), in patients with advanced solid tumors
Cancer Research·2025· 2 cited
Abstract 6941: Preclinical efficacy of the CK1 alpha/CDK7/CDK9 inhibitor BTX-A51 in <i>CIC</i>-rearranged sarcoma
Cancer Research·2025
Abstract 1180: Epigenetic dysregulation of IGF1 and PPARG2 in dedifferentiated liposarcoma
Cancer Research·2025
Improving Collection and Analysis of Overall Survival Data
Clinical Cancer Research·2024· 13 citedOpen Access
Supplementary Table S1 from Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
2024Open Access
Data from Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
2024Open Access
Supplementary Table S1 from Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
2024Open Access
Data from Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
2024Open Access
StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).
Journal of Clinical Oncology·2024· 5 cited
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
Clinical Cancer Research·2024· 7 cited
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
The Lancet·2024· 215 citedOpen Access
Abstract 604: Targeting casein kinase 1 alpha (CK1 alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas
Cancer Research·2024· 1 cited
Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas
JACC CardioOncology·2024· 15 citedOpen Access
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Journal of Clinical Oncology·2023· 141 cited
Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma
Cell Genomics·2023· 12 citedOpen Access
Data from Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody–Drug Conjugate
2023Open Access
Table S5 from Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes
2023Open Access
Table S6 from Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes
2023Open Access
page 1 of 32Next →

Frequent Co-authors

Christopher D.�M. Fletcher(20), Michael C. Heinrich(16), Margaret von Mehren(14), Jonathan A. Fletcher(13), Christopher L. Corless(13), Charles D. Blanke(10), Samuel Singer(10), Heikki Joensuu(10), Robert G. Maki(10), Annick D. Van den Abbeele(7), Jeffrey A. Morgan(7), Suzanne George(7), Jean‐Yves Blay(7), Burton Eisenberg(6), Peter Roberts‎(6), Saša Dimitrijević(6), Paolo G. Casali(6), Chang-Jie Chen(5), David A. Tuveson(4), Sandra Silberman(4)